Isofol Medical Logo

Isofol Medical

Developing a drug to enhance chemotherapy efficacy for solid tumors like colorectal cancer.

ISOFOL | ST

Overview

Corporate Details

ISIN(s):
SE0009581051
LEI:
549300MCXYAHG7VBHX75
Country:
Sweden
Address:
C/O Biotech Center, Arvid Wallgrens, 413 46 Göteborg
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Isofol Medical AB is a research-based biotechnology company focused on improving the prognosis for patients with severe forms of cancer. The company develops its primary drug candidate, arfolitixorin, with the aim of increasing the efficacy of first-line standard chemotherapy treatments for various solid tumors. A key area of development is colorectal cancer, where the company is conducting a Phase Ib/II clinical study to optimize the drug candidate's dosing regimen and therapeutic effect.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-23 10:45
Major Shareholding Notification
Swedish 10.5 KB
2025-08-26 08:00
Interim Report
Swedish 7.2 MB
2025-08-26 08:00
Interim Report
English 2.6 MB
2025-07-31 08:00
Declaration of Voting Results & Voting Rights Announcements
Nytt antal aktier och röster i Isofol
Swedish 60.6 KB
2025-07-31 08:00
Declaration of Voting Results & Voting Rights Announcements
New number of shares and votes in Isofol
English 61.3 KB
2025-07-04 18:00
Regulatory News Service
Isofol's rights issue fully subscribed – exercises overallotment for Japanese p…
English 128.5 KB
2025-07-04 18:00
Share Issue/Capital Change
Isofols företrädesemission övertecknad – utnyttjar övertilldelning till japansk…
Swedish 127.3 KB
2025-06-17 08:40
Prospectus
Isofol offentliggör prospekt i samband med bolagets företrädesemission
Swedish 98.7 KB
2025-06-17 08:40
Prospectus
Isofol publishes prospectus in connection with the company’s rights issue
English 119.6 KB
2025-06-11 14:00
Post-Annual General Meeting Information
Bulletin from extraordinary general meeting in Isofol Medical AB (publ) held on…
English 94.5 KB
2025-06-11 14:00
Post-Annual General Meeting Information
Kommuniké från extra bolagsstämma i Isofol Medical AB (publ) den 11 juni 2025
Swedish 74.5 KB
2025-06-05 08:30
Share Issue/Capital Change
Isofol offentliggör slutliga villkor i företrädesemission samt för en potentiel…
Swedish 142.5 KB
2025-06-05 08:30
Share Issue/Capital Change
Isofol announces final terms of the rights issue and the potential overallotmen…
English 167.4 KB
2025-05-21 16:40
Post-Annual General Meeting Information
Bulletin from annual general meeting in Isofol Medical AB (publ) held on May 21…
English 95.5 KB
2025-05-21 16:40
Post-Annual General Meeting Information
Kommuniké från årsstämma i Isofol Medical AB (publ) den 21 maj 2025
Swedish 90.1 KB

Automate Your Workflow. Get a real-time feed of all Isofol Medical filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Isofol Medical via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-01-11 Magnus Hurst Other Buy 35,000 24,150.00 SEK
2022-09-12 AB Windar Other Buy 500,000 305,000.00 SEK
2021-12-09 Tony Gustavsson Other Sell 58,767 858.00 SEK
2021-12-09 Tony Gustavsson Other Sell 58,767 152.79 SEK
2021-06-14 HealthCom GmbH Other Buy 233,336 1,493,350.40 SEK
2021-06-10 Gustaf Albèrt Other Other 15,153 96,979.20 SEK
2020-11-23 Tony Gustavsson Other Buy 58,767 43,487.58 SEK
2020-11-23 Tony Gustavsson Other Buy 58,767 29,971.17 SEK
2020-11-16 Sven Eriksson Other Sell 58,767 43,487.58 SEK
2020-11-16 Sven Eriksson Other Sell 58,767 29,971.17 SEK

Peer Companies

Company Country Ticker View
Developing novel cancer immunotherapies, including peptide vaccines and iPS-NKT cell therapies.
Japan 4594
Brilliant Future AB Logo
A data-driven survey platform to measure and improve employee & customer experiences.
Sweden BRILL
b-style holdings,Inc. Logo
Offers flexible staffing for homemakers and specialized recruitment for skilled professionals.
Japan 302A
BTS Group Logo
Helps organizations execute strategy via experiential learning for leadership and sales teams.
Sweden BTS
B.U Technology Logo
Commercializes university research via IP management, licensing, and new venture creation.
South Korea 230980
Advancing high-grade copper and precious metal projects from discovery to production.
Canada N/A
Cantargia Logo
Develops antibody treatments targeting IL1RAP for cancer and autoimmune/inflammatory diseases.
Sweden CANTA
Captor Therapeutics S.A. Logo
Developing TPD therapeutics for oncology and autoimmune diseases with its Optigrade™ platform.
Poland CTX
Offers one-stop BPO, CRM, and staffing for admin, manufacturing, and logistics.
Japan 6070
Carna Biosciences, Inc. Logo
Develops kinase inhibitor drugs for oncology/autoimmune diseases & offers discovery support services.
Japan 4572

Talk to a Data Expert

Have a question? We'll get back to you promptly.